Skip to content

Glyaderm in Pediatric Burns

Dermal Substitution in Paediatric Burns: A Prospective Case Series - Glyaderm in Paediatric Burns (GlyPeB)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON57502
Enrollment
20
Registered
2025-03-27
Start date
2022-10-20
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Full-thickness burns

Interventions

Intervention: Application of Glyaderm in combination with an autologous split thickness skin graft on debrided deep dermal or full thickness burn wounds.

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
No minimum to 15 Years

Inclusion criteria

Inclusion criteria: Full-thickness burnPediatric (< 16 years)Informed consent by parents (<12 years) or parents and patient (12-15 years old)

Exclusion criteria

Exclusion criteria: No informed consent Burn wound < 30 cm2 Clinically infected wounds

Design outcomes

Primary

MeasureTime frame
Main study parameters/endpoints: The main study parameter is the scar quality measured with the Patient and Observer Scar Assessment Scale (POSAS) observer scale at 3, 6 and 12 months post-operatively. 

Secondary

MeasureTime frame
To describe: - Graft take and wound epithelialization at 5-7 days postoperatively - Time to complete wound healing (>95% epithelialization) in days - Time to complete donor site healing in days - Wound/scar surface area at day of surgery and 3, 6 and 12 months post-operatively* - Scar quality using the POSAS patient scale, filled out by the parent at 3, 6 and 12 months post-operatively* - Quality of life using the TAPQOL (6 months to 24 months) or PedsQL (2-15 years) at 3, 6 and 12 months post-operatively. - Rate of scar hypertrophy during follow-up* - Rate of scar contractures during follow-up* - Range of motion (for affected joints) at 3, 6 and 12 months post-operatively* *if parents/patients are willing to extend their participation to 24, 36, 48 and 60 months, these variables will continue to be assessed.

Countries

Netherlands

Contacts

Public ContactM.S. Warenburg

Radboud Universitair Medisch Centrum

milly.vandewarenburg@radboudumc.nl(024) 361 95 94

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)